ArticleMolecular therapy oncolytics2020

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.

Liuya Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.